Back to discover
Drug

Beremagene geperpavec

Approved medicine
ClassCollagen alpha-1(VII) chain exogenous geneResearchOngoing clinical research
Also known as B-VEC, BVEC, Bercolagene telserpavec, Vyjuvek+1 more

B-VEC, BVEC, Bercolagene telserpavec, Vyjuvek, Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying).

RxNorm2637758ChEMBLCHEMBL4594328ATCD03AX16UNIIAQN7K24KQU
1
Active clinical trials
Collagen alpha-1(VII) chain
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Beremagene geperpavec
Aliases & brands
B-VECBVECBercolagene telserpavecVyjuvekDna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
RxNorm CUI
2637758
ChEMBL ID
CHEMBL4594328
ATC codes
D03AX16
UNII
AQN7K24KQU
Primary mechanism
Collagen alpha-1(VII) chain exogenous gene
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Collagen alpha-1(VII) chain
COL7A1 · Q02388
EXOGENOUS GENECollagen alpha-1(VII) chain exogenous gene

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2025-04-23
Latest approval
2025-04-23
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2025-04-23Approval
Approval: Vyjuvek (EMA)
Indication: Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain… Show full indication

Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
1
Active studies
1
Recruiting
PHASE DISTRIBUTIONn = 1
Phase 21
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.